Acer therapeutics receives formal dispute resolution request (fdrr) response from fda's office of new drugs

Acer therapeutics inc - receives formal dispute resolution request (fdrr) response from fda's office of new drugs.acer therapeutics - fda's office of new drugs has denied acer's appeal of complete response letter in relation to nda for edsivo.acer therapeutics - evaluating possible next steps with goal of resubmission of edsivo nda.acer therapeutics - believes cash position will be sufficient to fund its current operations through end of 2020, excluding some activities.
ACER Ratings Summary
ACER Quant Ranking